Wang, Zixi
Chen, Kenian
Jia, Yuemeng
Chuang, Jen-Chieh
Sun, Xuxu
Lin, Yu-Hsuan https://orcid.org/0000-0001-7910-570X
Celen, Cemre https://orcid.org/0000-0001-8308-3750
Li, Lin
Huang, Fang
Liu, Xin https://orcid.org/0000-0002-5646-423X
Castrillon, Diego H. https://orcid.org/0000-0001-6690-4633
Wang, Tao https://orcid.org/0000-0002-4355-149X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R03ES026397-01)
Cancer Prevention and Research Institute of Texas (RP150596, RP170267)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK111588)
EIF | Stand Up To Cancer (SU2C-AACR-IRG 10-16)
Stand Up To Cancer is a foundation in the US, but the box above forces me to use the UK foundation.
Article History
Received: 17 October 2019
Accepted: 3 August 2020
First Online: 7 September 2020
Competing interests
: At the time of publication, H.Z. owned Ionis Pharmaceuticals stock worth less than $US10,000 and has active collaboration with Alnylam Pharmaceuticals and Twenty-Eight Seven Therapeutics. The remaining authors declare no competing interests.